Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Aug;33(4):294-295.
doi: 10.37201/req/047.2020. Epub 2020 Jun 25.

[Baricitinib in the treatment of SARS-CoV-2 infection]

[Article in Spanish]
Affiliations
Comment

[Baricitinib in the treatment of SARS-CoV-2 infection]

[Article in Spanish]
M Gutiérrez-Lorenzo et al. Rev Esp Quimioter. 2020 Aug.
No abstract available

Keywords: Baricitinib; SARS-COV-2; hospital; infection; treatment.

PubMed Disclaimer

Conflict of interest statement

Los autores declaran no tener conflictos de intereses.

Comment on

References

    1. Richardson P, Griffin I, Tucker C, Smith D, Oechsle O, Phelan A et al. . Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020;395(10223):e30-e31. doi: 10.1016/s0140- 6736(20)30304-4 - DOI - PMC - PubMed
    1. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS): Tratamientos disponibles para el manejo de la infección respiratoria por SARS-CoV-2 [consultado 26/04/2020]. Disponible en: https://www.aemps.gob.es/la-aemps/ultima-informacion-de-la-aemps-acerca-...
    1. Cantini F, Niccoli L, Matarrese D, Nicastri E, Stobbione P, Golet-ti D. Terapia con baricitinib en COVID-19: un estudio piloto so-bre seguridad e impacto clínico. J Infect. 2020;. Doi: 10.1016/j.jinf.2020.04.017 - DOI - PMC - PubMed
    1. Praveen D, Puvvada R, M V. Janus kinase inhibitor baricitinib is not an ideal option for management of COVID-19. Int J Antimicrob Agents. 2020;:105967. doi:10.1016/j.ijantimicag.2020.105967 - DOI - PMC - PubMed